CABA

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Cabaletta Bio (CABA - Research Report), with a price target of $11.00. The company's shares closed yesterday at $2.03.According to TipRanks, Tsao is a 3-star analyst with an average return of 1.4% and a 38.44% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Cabaletta Bio, Revance Therapeutics, and Daré Bioscience.Cabaletta Bio has an analyst consensus of Strong Buy, with a price target consensus of $8.20, implying a 303.94% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $10.
https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-cabaletta-bio-caba?utm_source=advfn.com&utm_medium=referral